| Filed On | Filing |
|---|---|
| 27 Oct 2026 |
8-K: Other Events
Date of Report (Date of earliest event reported): October 27, 2026 |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure
Tafenoquine for Babesiosis Progress across acute, relapsing and chronic disease Geoffrey S. Dow, PhD Chief Executive Officer 2026 ILADS Annual Scientific Conference October 22–25, 2026 | Herndon, Virginia Reframing Complex Disease: Pathw... |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Tafenoquine for Severe Babesiosis Study Interim Data Readout Webinar October 6, 2026 Today's discussion • Clinical context and current standard of care • Published evidence supporting tafenoquine + atovaquone • Hospital study interim ana... |
| 14 Sep 2026 |
8-K: Other Events
On September 12, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60P”) submitted a Statement of Interest to the U.S. Food and Drug Administration (“FDA”) requesting a Commissioner’s National Priority Voucher (“CNPV”) designated... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
H.C. Wainwright Presentation 60 Degrees Pharmaceuticals, Inc. September 2026 Targeted therapies for vector-borne disease Investment focus A marketed antimalarial platform creates a path to potential indication expansion in babesiosis Com... |
| 25 Aug 2026 | EFFECT |
| 17 Aug 2026 | DELAYING AMENDMENT |
| 14 Aug 2026 | REGISTRATION STATEMENT |
| 14 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 05 Aug 2026 | SCHEDULE 13G |
| 04 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 29 Jul 2026 |
Form 3: Knight Therapeutics Inc., 10% owner
Holds 658,629 shares of Common Stock, $0.0001 par value per share |
| 29 Jul 2026 | SCHEDULE 13G |
| 20 Jul 2026 | 8-K: Regulation FD Disclosure |
| 09 Jul 2026 | 8-K: Other Events |
| 02 Jul 2026 | Proxy statement: annual meeting on August 5, 2026 |
| 15 Jun 2026 |
Form 4: Dow Geoffrey S, Director
Bought 7,350 shares ($10.1K) |
| 08 Jun 2026 | PRELIMINARY PROXY STATEMENT |
| 03 Jun 2026 | 8-K: Other Events |
Loading...
